Northway Biotech would like to announce that UAB Biotechpharma has successfully implemented the project “Biosimilar monoclonal antibody fragment synthesis in E. coli, manufacturing technology generation and capacity upscaling to 3000L”, which was financed according to the 2014-2020 European Union Investment Funds program, Priority No. 1 “Promotion of scientific research, experimental development and innovation”, No. J05-LVPA-K “Intelektas. Bendri mokslo – verslo projektai” invitation No. 3. Northway Biotech received EUR 3,9 million support, while the total project investment reached about EUR 15 million.
During the implementation of the project, Northway Biotech developed a novel manufacturing technology of high efficacy Certolizumab pegol monoclonal antibody using microbial host, which produces at least 10 times higher yield, keeping industry frontier quality. A breakthrough as such will not only reduce the costs of production, accelerate manufacturing processes and significantly increase product yield but would also provide the market with a high volume of a prospective therapeutic drug. Sequentially, this should encourage further preclinical and clinical research potentially expanding Certolizumab’s therapeutic areas and driving the drug costs down for patients worldwide, including those suffering from autoimmune diseases.